Significant Rise in Insurance Denials for Brand-Name Prescription Drugs

A recent analysis conducted by Johns Hopkins Bloomberg School of Public Health and the American Enterprise Institute reveals a significant rise in insurance denials for initial requests to fill prescriptions of brand-name drugs without generic alternatives. The study examined over two million prescription attempts across various insurance plans, highlighting an increase in initial rejection rates from 24.3% in 2018 to 40.7% in 2024, a 67% surge. Alarmingly, nearly half of those initially denied did not receive an alternative medication within the same class within 90 days, and those who eventually received treatment faced an average delay of 12 days.

Of the initial prescription attempts, 32% were turned down due to formulary exclusions or utilization management protocols. These insurance guidelines often require prior approval or stipulate trials with alternative therapies before covering the prescribed brand-name drug. The growing implementation of such policies is identified as the primary driver of increased rejections. Notably, commercial and Medicaid managed care plans have experienced substantial boosts in these restrictions.

Joseph Levy, PhD, the study's lead author, commented on the significant impact of these insurance policies on patient medication accessibility, noting the balance between cost management and potential delays in obtaining necessary treatments. Published in JAMA, the study underscores that while brand-name drugs account for only 10% of all prescriptions, they represent 88% of drug spending due to their lack of generic options.

Market Data and Prescription Trends

Market data for 2024 show brand-name prescriptions resulted in expenses totaling approximately $700 billion, whereas generics and biosimilars made up around 90% of filled prescriptions, with a lesser expense of $98 billion. The data analysis, sourced from IQVIA's Formulary Impact Analyzer, included 1.17 million individuals attempting to fill prescriptions for single-source brand-name medications. Rejection rates varied across therapeutic classes, with incretin-based therapies seeing an 85% rejection rate, while oral anticoagulants had a 6.7% rate.

Insurer responses differed by coverage type, with the highest rejection rates observed within ACA marketplace and Medicaid-managed care plans compared to Medicare plans. The study highlights the complexities of real-time insurance restrictions at the point of prescribing, often unknown to clinicians. Simplifying prior authorization processes is suggested to mitigate unnecessary delays, although this could potentially lead to increased drug costs.

Emphasizing the need to evolve these policies, the research underscores the importance of balancing cost-effectiveness and timely patient access to medications. The study was supported by Arnold Ventures and involved collaboration through the Johns Hopkins University-American Enterprise Institute Fellowship Exchange Program.